FDA greenlights at-home starting dose for lecanemab, a first for Alzheimer's treatment
Alzheimer's patients can now start treatment at home. The FDA has approved a subcutaneous (SC) starting dose of lecanemab (Leqembi IQLIK), allowing patients or caregivers to self-administer the drug via autoinjector rather than visiting an infusion clinic. The SC formulation showed bioequivalent drug exposure and comparable amyloid-clearing effects to the IV version, with a consistent safety profile.
Wegovy gets green light in India for fatty liver disease treatment
FDA greenlights at-home subcutaneous Leqembi for Alzheimer's patients
Whole blood vs. blood components in trauma: No survival edge found
IgA nephropathy treatment landscape expands with two new FDA approvals
One year later, insurers' prior authorization pledge is falling short
New AHA/ACC guideline tackles heart, kidney, and metabolic health as one
FDA upgrades Retevmo to traditional approval for RET fusion-positive solid tumors
UK recommends MenB vaccine for all 15-year-olds after country's largest-ever outbreak
FDA accepts NDA for first-of-its-kind oral pill targeting obstructive sleep apnea
Finerenone could be a "foundational therapy" for kidney disease — even without diabetes
Explore all the latest healthcare news and insights